Circadian Lighting Association (CLA) an international association of manufacturers of lighting products for treating SAD (Seasonal Affective Disorder) and other circadian concerns.
Bright Light Therapy devices to help regulate circadian rhythms and treat Seasonal Affective Disorder (SAD)
Bluwave™ Apollo Bluewave Therapy provides higher effective response than most full spectrum lights. It delivers only the most effective wavelengths of blue light spectrum which is the most effective color or wavelength; thus providing better result than most spectrum light and at only ten percent of the intensity of a regular 10,000 lux lamp. Hence, light therapy is not just convenient but also easier on the eyes with fewer side effects.
Center for Sleep & Wake Disorders is a full service sleep center caring for patients with all disorders of sleep and wakefulness. Helene A. Emsellem, MD is the Medical Director.
Circadian Sleep Disorders Network is a 501(c)(3) nonprofit organization promoting awareness, accommodation, support, and research around the issues of Circadian Rhythm Sleep Disorders (CRSDs).
Non-24-Hour Sleep-Wake Disorder Non-24 is a serious, chronic circadian rhythm disorder (CRSD) very common in people who are totally blind, and it can arise at any age.
What is Non-24? Non-24-Hour Sleep-Wake Disorder (Non-24) is a serious, chronic disorder that disrupts a person’s circadian rhythms. Non-24 affects up to 70% of people who are totally blind, whether you were born blind or became so later in life. New
Non-24-hour sleep–wake disorder Wikipedia defines it as a "complaint of insomnia or excessive sleepiness related to abnormal synchronization between the 24-hour light–dark cycle and the endogenous circadian rhythms of sleep and wake propensity".
About HETLIOZ® (tasimelteon) The first and only FDA-approved treatment for Non-24-Hour Sleep-Wake Disorder (Non-24). Updated
Tasimelteon (trade name Hetlioz) is a drug approved by the U.S. Food and Drug Administration (FDA) in January 2014 for the treatment of non-24-hour sleep–wake disorder (also called non-24, N24, and N24HSWD). In June 2014, the European Medicines Agency accepted an EU filing application for tasimelteon and in July 2015, the drug was approved in Europe for the treatment of non-24-hour sleep-wake rhythm disorder in totally blind adults, but not in the rarer case of non-24 in sighted people. by Wikipedia New
Sleep Apnea from MedlinePlus National Institutes of Health
Sleep Disorders Guide has descriptions, symptoms, causes, and treatments of various sleep disorders such as sleep apnea, insomnia, snoring, restless legs, and narcolepsy.
on